Tumor markers telomerase

Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett 2003 94 221-33. 

Dictyodendrin alkaloids have been described as the first telomerase inhibitors of marine origin and hence represent potential lead compounds in the quest for small molecule inhibitors of the tumor-marker enzyme. In a 2009 study, Fiirstner et al. [58] reported the synthesis of several members of the series, making use of FI—HMBC data. 

Telomerase is normally active during embryogenesis, but is repressed in most somatic cells before or shortly after birth. Germline cells, activated lymphocytes, and other immortal cells show no shortening of telomere length and possess telomerase activity. Thus tumor cells should also show telomerase activity that can act as a specific marker of transformation. 

Eiedler W, Hoppe C, Schimmel B, et al. Molecular characterization of head and neck tumors by analysis of telomerase activity and a panel of microsatellite markers. Int J Mol Med. 2002 9(4) 417-423. 

Telomerase, described as a ribonucleoprotein enzyme that extends the sequences at the chromosomal ends (telomeres), is another strong candidate for a marker. It is active in over 90% of primary human tumors, but for the most part is inactive in normal cells. (As noted earlier, however, in hmited or inactive amounts it produces no changes, but in excess it leads to cancer, that is, unregulated cell growth.)... 

---